What Viracta Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Pomerantz Roger | Director | Nov 25 | Exercise / conversion · M | +9,034 | — | — | 126,478 |
| Royston Ivor | Director | Nov 25 | Exercise / conversion · M | +25,219 | — | — | 839,741 |
| Pomerantz Roger | Director | Aug 25 | Exercise / conversion · M | +9,034 | — | — | 117,444 |
| Royston Ivor | Director | Aug 25 | Exercise / conversion · M | +25,219 | — | — | 814,522 |
| Pomerantz Roger | Director | May 25 | Exercise / conversion · M | +9,035 | — | — | 108,410 |
| Royston Ivor | Director | May 25 | Exercise / conversion · M | +25,219 | — | — | 789,303 |
| Chevallard Daniel R. | CFO and COO | Feb 27 | Open-market sale · S | −3,405 | $0.73 | −$2.49K | 102,306 |
| Pomerantz Roger | Director | Feb 25 | Exercise / conversion · M | +9,034 | — | — | 99,375 |
| Chevallard Daniel R. | CFO and COO | Feb 25 | Exercise / conversion · M | +6,889 | — | — | 105,711 |
| Royston Ivor | Director | Feb 25 | Exercise / conversion · M | +25,219 | — | — | 764,084 |
| Rothera Mark | President and CEO | Dec 01 | Open-market buy · P | +47,906 | $0.49 | +$23.6K | 100,000 |
| Rothera Mark | President and CEO | Nov 30 | Open-market buy · P | +52,094 | $0.49 | +$25.7K | 52,094 |
| Chevallard Daniel R. | CFO and COO | Nov 28 | Open-market sale · S | −3,720 | $0.50 | −$1.86K | 98,822 |
| Pomerantz Roger | Director | Nov 25 | Exercise / conversion · M | +9,034 | — | — | 90,341 |
| Royston Ivor | Director | Nov 25 | Exercise / conversion · M | +25,219 | — | — | 738,865 |
| Chevallard Daniel R. | CFO and COO | Nov 25 | Exercise / conversion · M | +6,889 | — | — | 102,542 |
| Chevallard Daniel R. | CFO and COO | Aug 28 | Open-market sale · S | −3,512 | $1.45 | −$5.09K | 95,653 |
| Pomerantz Roger | Director | Aug 25 | Exercise / conversion · M | +9,034 | — | — | 81,307 |
| Royston Ivor | Director | Aug 25 | Exercise / conversion · M | +25,219 | — | — | 713,646 |
| Chevallard Daniel R. | CFO and COO | Aug 25 | Exercise / conversion · M | +6,888 | — | — | 99,165 |
Loading...
